Compare Nuwellis Inc (NUWE) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Banco Santander SA — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Banco Santander SA trades at $13.53 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 87663.6× Nuwellis Inc's market cap, and Banco Santander SA pays a 2.06% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Banco Santander SA for 55 Days on average.
| NUWE | SAN | |
|---|---|---|
Market Cap | $2.20M | $192.86B |
Volume | 121,544 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $146.65 | $15.05 |
52-Week Low | $0.68 | $9.65 |
Typical Hold Time | 26 Days | 55 Days |
Enterprise Value | -$1.52M | $360.86B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Banco Santander (SAN) trades at $13.66, down 2.5% today, with technical indicators showing bearish momentum. The company reported strong fundamentals with Q2 2026 net income of $14.10 billion and a 26.25% net margin, though cash flow trends show recent operational challenges. Recent developments include the completion of the Webster Financial acquisition, expanding Santander's U.S. presence and diversification.
Outlook remains mixed with analyst consensus at 'Moderate Buy' (64% buy ratings) but technical weakness. Key opportunities include record profitability and strategic acquisitions, while risks involve declining cash flows and high debt levels. The stock's valuation appears reasonable with P/E of 13.55 and P/B of 1.58.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
